Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021

Klein, Nicola P.Stockwell, Melissa S.Demarco, MariaGaglani, ManjushaKharbanda, Anupam B.Irving, Stephanie A.Rao, SuchitraGrannis, Shaun J.Dascomb, KristinMurthy, KempapuraRowley, Elizabeth A.Dalton, Alexandra F.DeSilva, Malini B.Dixon, Brian E.Natarajan, KarthikStenehjem, EdwardNaleway, Allison L.Lewis, NedOng, Toan C.Patel, PalakKonatham, DeepikaEmbi, Peter J.Reese, Sarah E.Han, JungmiGrisel, NancyGoddard, KristinBarron, Michelle A.Dickerson, MonicaLiao , I-ChiaFadel, William F.Yang, Duck-HyeArndorfer, JulieFireman, BruceGriggs, Eric P.Valvi, Nimish R.Hallowell, CarlyZerbo, OussenyReynolds, SueFerdinands, JillWondimu, Mehiret H.Williams, JeremiahBozio, Catherine H.Link-Gelles, RuthAzziz-Baumgartner, EduardoSchrag, Stephanie J.Thompson, Mark G.Verani, Jennifer R.2024-06-202024-06-202022-03-04Klein, N. P. (2022). Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years—VISION Network, 10 States, April 2021–January 2022. MMWR. Morbidity and Mortality Weekly Report, 71. https://doi.org/10.15585/mmwr.mm7109e3https://hdl.handle.net/1805/41678en-USPublisher PolicyBNT162b2 (Pfizer-BioNTech) vaccineCOVID-19vaccine effectiveness (VE)Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022Article